Maternal Buprenorphine-naloxone Treatment and the Infant
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 42 people enrolled
- Started
- 1 Jun 2018
- Ended
- 15 Dec 2023
- Type of study
- Interventional
- Treatments tested
- fetal monitoring
- Buprenorphine Naloxone
- Record updated
- 26 February 2024
Who can take part
- Age
- 18 years to 44 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Current opioid use disorder (OUD) as defined by DSM V criteria
- singleton pregnancies, generally uncomplicated by conditions that jeopardize pregnancy outcome
- Gestation less than 24 weeks
Who cannot take part
- Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery
- Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension
- Alcohol use disorder per DSM V criteria (see ascertainment methods below)
- Evidence of fetal malformation detected by prenatal ultrasound
- Significant maternal psychopathology that would preclude informed consent
- Women stable on methadone maintenance (defined as more than 3 consecutive days of dosing)
- Women coming to treatment reporting "street" methadone use (for more than 3 consecutive days
- Women not planning to receive obstetric care at the Center for Addiction and Pregnancy; - Women not planning to deliver their infants at Johns Hopkins Bayview Medical center
- Women planning for adoption of their infant
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
The purpose of this mechanistic study is to evaluate the effects that maternal buprenorphine-naloxone maintenance have on the neurobehavioral development of the fetus and infant. To accomplish this, the investigators will study a sample of 120 opioid dependent pregnant women that will receive buprenorphine-naloxone as part of substance abuse treatment at a comprehensive care treatment facility for pregnant and parenting women with substance use disorders. Fetal neurobehavior and maternal physiology will be assessed, via an established maternal-fetal data acquisition system, at 4 points during gestation: 24, 28, 32 and 36 weeks. Infant birth parameters and Neonatal Abstinence Syndrome (NAS) spectrum display will be evaluated at birth, and infant neurodevelopment will be assessed during the first month of life.
The group in the trial
- Buprenorphine-naloxone treatedTreatment being tested
Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
Treatment: fetal monitoring and Buprenorphine Naloxone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Maternal Buprenorphine-naloxone Treatment During the Perinatal Period: Fetal and Infant Effects
- Record updated
- 26 February 2024